Novo Nordisk stock tumbled Friday after its weight-loss drug Wegovy landed on Medicare's next list of drugs to face price negotiations.

(MENAFN- EIN Presswire) Exocrine pancreatic insufficiency companies working in the market are AbbVie, Nestle, Digestive Care, Abbott, Orlando Health, Chiesi Farmaceutici, and others. LAS VEGAS, NV ...

It's encouraging to see that AbbVie has been growing its earnings per share at 5.7% a year over the past five years. While EPS is growing at a decent rate, but future growth could be limited by ...

In its latest attempt to bulk up its cancer drug portfolio, AbbVie has signed a new licensing agreement with China-based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer ...

AbbVie, with a market cap of over $300 billion, shows strong cash flow potential despite patent expirations, making it a valuable investment. The company reported strong 3Q financials, with ...

AbbVie will write off $3.5 billion related to its $8.7 billion investment in Cerevel Therapeutics following the failure of the company's key schizophrenia drug, emraclidine, The Wall Street ...

AbbVie and Anima Biotech have announced that they are collaborating in a deal worth up to over $580 million to discover and develop drugs that modulate mRNA biology for three targets in cancer and ...

AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a preclinical-stage, oral drug for psoriasis. US-based Nimble was set up in ...

AbbVie will take an impairment charge of approximately $3.5 billion related to the back-to-back failures of its pricey drug candidate emraclidine in two mid-stage schizophrenia trials, the pharma ...